Biogen Idec announced that the European Commission (EC) has granted approval to AVONEX PEN for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event.
Douglas E. Williams, Ph.D., Executive Vice President, Research and Development at Biogen Idec, At Biogen Idec, our commitment to the MS community is unwavering. We strive to meet the needs of all MS patients by harnessing our extensive expertise in neurology and through our commitment to research and innovation.
For more than 10 years, AVONEX has been the therapy of choice for many MS patients who prefer the convenience of once-weekly injections, along with its proven efficacy and a well-established safety profile. Not only do we think AVONEX PEN makes AVONEX therapy more convenient, it can also help alleviate the anxiety that some MS patients feel when they have to inject their medication.
